🟢 Capricor Therapeutics is trading 10.33% up in pre-market with no newly identified company-specific catalyst

Capricor Therapeutics is trading at $6.94, up 10.33% in pre-market on August 24, 2026, with no newly identified company-specific announcement explaining the gain.

• The latest major company update was the August 13, 2026 second-quarter report, which noted deramiocel’s active FDA review.
• Recent volatility followed FDA-related deramiocel developments, including the agency’s willingness to review additional data.
• The broader market was weaker, so global sentiment does not clearly explain the rise.